These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 34199304)

  • 21. Fibroblast growth factor receptor fusions in cancer: opportunities and challenges.
    Chen L; Zhang Y; Yin L; Cai B; Huang P; Li X; Liang G
    J Exp Clin Cancer Res; 2021 Nov; 40(1):345. PubMed ID: 34732230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical development and management of adverse events associated with FGFR inhibitors.
    Subbiah V; Verstovsek S
    Cell Rep Med; 2023 Oct; 4(10):101204. PubMed ID: 37757826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring
    Meric-Bernstam F; Bahleda R; Hierro C; Sanson M; Bridgewater J; Arkenau HT; Tran B; Kelley RK; Park JO; Javle M; He Y; Benhadji KA; Goyal L
    Cancer Discov; 2022 Feb; 12(2):402-415. PubMed ID: 34551969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma.
    Uson PLS; Bearss J; Babiker HM; Borad M
    Expert Opin Drug Saf; 2023; 22(8):637-641. PubMed ID: 37363820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention and treatment of FGFR inhibitor-associated toxicities.
    Mahipal A; Tella SH; Kommalapati A; Yu J; Kim R
    Crit Rev Oncol Hematol; 2020 Nov; 155():103091. PubMed ID: 32961472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use.
    Ito S; Otsuki S; Ohsawa H; Hirano A; Kazuno H; Yamashita S; Egami K; Shibata Y; Yamamiya I; Yamashita F; Kodama Y; Funabashi K; Kazuno H; Komori T; Suzuki S; Sootome H; Hirai H; Sagara T
    ACS Med Chem Lett; 2023 Apr; 14(4):396-404. PubMed ID: 37077386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201.
    Necchi A; Pouessel D; Leibowitz R; Gupta S; Fléchon A; García-Donas J; Bilen MA; Debruyne PR; Milowsky MI; Friedlander T; Maio M; Gilmartin A; Li X; Veronese ML; Loriot Y
    Ann Oncol; 2024 Feb; 35(2):200-210. PubMed ID: 37956738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The future of fibroblast growth factor receptor inhibitors and mechanisms of resistance for cholangiocarcinoma.
    Ruff SM; Roychowdhury S; Pawlik TM
    Expert Opin Pharmacother; 2023 May; 24(7):779-788. PubMed ID: 37042129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics.
    Chandana SR; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2020 Dec; 29(12):1413-1429. PubMed ID: 33074030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue.
    Rizzo A; Ricci AD; Frega G; Di Federico A; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):567-574. PubMed ID: 33787429
    [No Abstract]   [Full Text] [Related]  

  • 31. Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors.
    Facchinetti F; Hollebecque A; Bahleda R; Loriot Y; Olaussen KA; Massard C; Friboulet L
    Clin Cancer Res; 2020 Feb; 26(4):764-774. PubMed ID: 31585937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calciphylaxis Cutis Associated With Fibroblast Growth Factor Receptor (FGFR) Inhibitor Therapy: A New Challenge.
    Griffith P; Jedrych J; Sunshine J; Laheru DA; Yarchoan M
    Cureus; 2022 Jan; 14(1):e21478. PubMed ID: 35223258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.
    Wu L; Zhang C; He C; Qian D; Lu L; Sun Y; Xu M; Zhuo J; Liu PCC; Klabe R; Wynn R; Covington M; Gallagher K; Leffet L; Bowman K; Diamond S; Koblish H; Zhang Y; Soloviev M; Hollis G; Burn TC; Scherle P; Yeleswaram S; Huber R; Yao W
    J Med Chem; 2021 Aug; 64(15):10666-10679. PubMed ID: 34269576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.
    Facchinetti F; Loriot Y; Brayé F; Vasseur D; Bahleda R; Bigot L; Barbé R; Nobre C; Combarel D; Michiels S; Italiano A; Smolenschi C; Tselikas L; Scoazec JY; Ponce-Aix S; Besse B; André F; Olaussen KA; Hollebecque A; Friboulet L
    Clin Cancer Res; 2024 Nov; 30(21):4943-4956. PubMed ID: 39226398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment.
    Wang S; Burgess M; Major C; English A; Sweeney M; Hartmann A
    J Pathol Clin Res; 2020 Jul; 6(3):207-214. PubMed ID: 32304281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Derazantinib: an investigational drug for the treatment of cholangiocarcinoma.
    Braun S; McSheehy P; Litherland K; McKernan P; Forster-Gross N; Bachmann F; El-Shemerly M; Dimova-Dobreva M; Polyakova I; Häckl M; Zhou P; Lane H; Kellenberger L; Engelhardt M
    Expert Opin Investig Drugs; 2021 Nov; 30(11):1071-1080. PubMed ID: 34698609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting FGFRs Using PD173074 as a Novel Therapeutic Strategy in Cholangiocarcinoma.
    Balasubramanian B; Yacqub-Usman K; Venkatraman S; Myint KZ; Juengsamarn J; Sarkhampee P; Lertsawatvicha N; Sripa J; Kuakpaetoon T; Suriyonplengsaeng C; Wongprasert K; Grabowska AM; Bates DO; Janvilisri T; Tohtong R
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma.
    Lyou Y; Grivas P; Rosenberg JE; Hoffman-Censits J; Quinn DI; P Petrylak D; Galsky M; Vaishampayan U; De Giorgi U; Gupta S; Burris H; Rearden J; Li A; Wang H; Reyes M; Moran S; Daneshmand S; Bajorin D; Pal SK
    Eur Urol; 2020 Dec; 78(6):916-924. PubMed ID: 32847703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Robust Response to Futibatinib in a Patient With Metastatic FGFR-Addicted Cholangiocarcinoma Previously Treated Using Pemigatinib.
    Rengan AK; Denlinger CS
    J Natl Compr Canc Netw; 2022 Apr; 20(5):430-435. PubMed ID: 35378504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors.
    Doi T; Shitara K; Kojima T; Kuboki Y; Matsubara N; Bando H; Yoh K; Naito Y; Hirai H; Kurokawa Y; Kato T; Morizane C
    Cancer Sci; 2023 Feb; 114(2):574-585. PubMed ID: 35838190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.